Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan R Brody

Showing results (11-20 of 170) with videos related to

Pageof 17
Sort By:
Cancer Research|September 16, 2024
The Pivotal Role of Germline BRCA2 Pathogenic Variants in "Apparently Sporadic" Pancreatic CancerJonathan R Brody, Alison P Klein
Wiley Interdisciplinary Reviews. RNA|September 30, 2011
HuR's role in gemcitabine efficacy: an exception or opportunity?Jonathan R Brody, Gregory E Gonye
Cancer Biology & Therapy|July 6, 2007
No K01 offered from the NCI What's the message?Jonathan R Brody, Thomas N Tulenko
The Journal of Surgical Research|October 19, 2024
A Surgeon-Scientist's Pursuit of the Elusive R01Jordan M Winter, Jonathan R Brody
The American Journal of Pathology|August 17, 2014
Fusing transcriptomics to progressive prostate cancerMasaya Jimbo, Karen E Knudsen, Jonathan R Brody
Seminars in Oncology|March 2, 2015
Novel targets in pancreatic cancer researchGeoffrey Kozak, Fernando F Blanco, Jonathan R Brody
Cancer Journal (Sudbury, Mass.)|November 29, 2012
Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box"Renee Tholey, Janet A Sawicki, Jonathan R Brody
Cell Cycle (Georgetown, Tex.)|December 9, 2014
Upgrading gemcitabine with recycled kinase inhibitorsFernando F Blanco, Michael J Pishvaian, Jonathan R Brody
Cancer Biology & Therapy|April 1, 2006
Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literatureJordan M Winter, Jonathan R Brody, Scott E Kern
Advances in Surgery|September 30, 2011
The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancerJonathan R Brody, Agnieszka K Witkiewicz, Charles J Yeo
Pageof 17

Showing results (11-20 of 170) with videos related to

Sort By:
Pageof 17
Cancer Research|September 16, 2024
The Pivotal Role of Germline BRCA2 Pathogenic Variants in "Apparently Sporadic" Pancreatic CancerJonathan R Brody, Alison P Klein
Wiley Interdisciplinary Reviews. RNA|September 30, 2011
HuR's role in gemcitabine efficacy: an exception or opportunity?Jonathan R Brody, Gregory E Gonye
Cancer Biology & Therapy|July 6, 2007
No K01 offered from the NCI What's the message?Jonathan R Brody, Thomas N Tulenko
The Journal of Surgical Research|October 19, 2024
A Surgeon-Scientist's Pursuit of the Elusive R01Jordan M Winter, Jonathan R Brody
The American Journal of Pathology|August 17, 2014
Fusing transcriptomics to progressive prostate cancerMasaya Jimbo, Karen E Knudsen, Jonathan R Brody
Seminars in Oncology|March 2, 2015
Novel targets in pancreatic cancer researchGeoffrey Kozak, Fernando F Blanco, Jonathan R Brody
Cancer Journal (Sudbury, Mass.)|November 29, 2012
Molecular-based and alternative therapies for pancreatic cancer: looking "out of the box"Renee Tholey, Janet A Sawicki, Jonathan R Brody
Cell Cycle (Georgetown, Tex.)|December 9, 2014
Upgrading gemcitabine with recycled kinase inhibitorsFernando F Blanco, Michael J Pishvaian, Jonathan R Brody
Cancer Biology & Therapy|April 1, 2006
Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literatureJordan M Winter, Jonathan R Brody, Scott E Kern
Advances in Surgery|September 30, 2011
The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancerJonathan R Brody, Agnieszka K Witkiewicz, Charles J Yeo
Pageof 17